CRF-R1 Antagonist Treatment Exacerbates Circadian Corticosterone Secretion under Chronic Stress, but Preserves HPA Feedback Sensitivity

Despite promising initial reports, corticotropin-releasing factor receptor type-1 (CRF-R1) antagonists have mostly failed to display efficacy in clinical trials for anxiety or depression. Rather than broad-spectrum antidepressant/anxiolytic-like drugs, they may represent an ‘antistress’ solution for...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibarguen-Vargas, Yadira, Leman, Samuel, Palme, Rupert, Belzung, Catherine, Surget, Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707167/
https://www.ncbi.nlm.nih.gov/pubmed/34959395
http://dx.doi.org/10.3390/pharmaceutics13122114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707167/
https://www.ncbi.nlm.nih.gov/pubmed/34959395
http://dx.doi.org/10.3390/pharmaceutics13122114

Ejemplares similares